Roth Capital Partners initiated coverage of Evofem Biosciences (NASDAQ:EVFM) with a “buy” rating and $15 price target. The stock closed at $3.30 on June 19. Analyst Yasmeen Rahimi writes that the time is ripe for...

Echelon Wealth Partners hiked its price target for Neptune Wellness Solutions (TSX, NASDAQ:NEPT) to $8 from $5.25 after the company struck a strategic medical cannabis oil agreement with Canopy Growth (TSX:WEED). Shares...

H.C. Wainwright initiated coverage of Arcadia Biosciences (NASDAQ:RKDA) with a “buy” rating and $20 price target. The stock closed at $8.16 on June 18. Arcadia has a track record in the generation of productivity traits...

BTIG downgraded Helius Medical Technologies (NASDAQ:HSDT) to “neutral” from “buy” but maintained its $14 price target, saying it is uneasy about regulatory and fundraising timelines. The stock closed at $12.87 on June...

Leerink launched coverage of Iterum Therapeutics (NASDAQ:ITRM) with an “outperform” rating and price target of $18. The stock closed at $12 on June 18. Iterum is developing an IV and oral formulation of sulopenem for...

Leerink resumed coverage of Innate Pharma (Euronext Paris: FR0010331421 – IPH) with an “outperform” rating and price target of €9. The stock closed at €5.28 on June 13. Innate is developing therapeutic antibodies that...

Ladenburg Thalmann downgraded Flex Pharm (NASDAQ:FLKS) to “neutral” from “buy” without a price target after the company halted two Phase 2 trials. In afternoon trading on June 13, shares of Flex were quoted at $1.36...

Mackie Research initiated coverage of Aleafia Health (TSXV:ALEF) with a “buy” rating and price target of $1.75. The stock closed at 51 cents on June 12. Aleafia runs the largest network of referral-only medical cannabis...

Roth Capital Partners initiated coverage of Stemline Therapeutics (NASDAQ:STML) with a “buy” rating and $30 price target. The stock closed at $17.90 on June 11. “We expect Stemline to sail smoothly through a biologics...

Canaccord Genuity raised its price target for Tactile Systems Technology (NASDAQ:TCMD) to $56 from $46 on the heels of a recent acquisition of IP. The stock closed at $51.37 on June 11. Tactile is a medical device...

Roth Capital Partners resumed coverage of LeMaitre Vascular (NASDAQ:LMAT) with a “buy” rating and $38 price target. The stock closed at $33.77 on June 7. LeMaitre offers disposable medical devices, implants (synthetic...

H.C. Wainwright initiated coverage of Axsome Therapeutics (NASDAQ:AXSM) with a “buy” rating and price target of $10. The stock closed at $3.60 on June 6. Axsome, which is focused on central nervous system (CNS)...

H.C. Wainwright initiated coverage of Voyager Therapeutics (NASDAQ:VYGR) with a “buy” rating and $30 price target, saying the company is assembling a neuro-focused gene therapy franchise. The stock closed at $20.41 on...

Roth Capital Partners hiked its price target for Viking Therapeutics (NASDAQ:VKTX) to $13 from $7.50, saying Viking is the beneficiary of competitive data that validates its VK2809 drug candidate. The stock closed at $9...

Leerink upgraded T2 Biosystems (NASDAQ:TTOO) to “outperform” from “market perform” and raised its price target to $12 from $5. The stock closed at $7.74 on May 31. Analyst Puneet Souda writes that this week’s...

Ladenburg Thalmann upgraded Arcturus Therapeutics (NASDAQ:ARCT) to “buy” from “neutral” with a $22 price target after the company resolved a management dispute, “removing an organizational overhang since early February...

BTIG raised its price target for Exact Sciences (NASDAQ:EXAS) to $70 from $60 after the American Cancer Society expanded colorectal cancer screening guidelines. Shares of Exact were quoted at $57.99, up 10%, in...

BTIG launched coverage of ASLAN Pharmaceuticals (NASDAQ:ASLN) with a “buy” rating and $16 price target. The stock closed at $6.85 on May 29. Singapore-based ASLAN is engaged in the development and commercialization of...

H.C. Wainwright initiated coverage of G1 Therapeutics (NASDAQ:GTHX) with a “buy” rating and a $61 price target based on an outlook of the company’s pipeline. The stock closed at $49.20 on May 29. G1’s pipeline...